ID: MRFR/Pharma/4597-HCR | August 2022 | Region: Global | 100 Pages
Table of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porterβs Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Adenomyosis Market, by Type
6.1 Introduction
6.2 Focal
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
6.3 Adenomyoma
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
6.4 Diffuse
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7. Global Adenomyosis Market, by Treatment
7.1 Introduction
7.2 Anti-Inflammatory Drugs
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.2.1 Ibuprofen
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.2.2 Naproxen
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.3 Hormone Medications
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.3.1 Combined Estrogen-Progestin Pills
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.3.2 Vaginal Rings
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.3.3 Hormone-Containing Patches
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
7.3.4 Aromatase Inhibitors
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
β’
7.4 Hysterectomy
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8. Global Adenomyosis Market, by Diagnosis
8.1 Introduction
8.2 Ultrasound
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8.3 MRI
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8.4 Historiography
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8.5 Hysteroscopy
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8.6 Cystoscopy
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
8.7 Laparoscopy
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
9. Global Adenomyosis Market, by End-User
9.1 Introduction
9.2 Hospitals & Clinics
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
9.3 Ambulatory Surgical Centers
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
9.4 Research Institutes
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
9.5 Others
β’ Market Estimates & Forecast, 2020β2027
β’ Market Estimates & Forecast, by Region/Country, 2020β2027
10 Global Adenomyosis Market, by Region
10.1 Introduction
10.2 Americas
β’ Market Estimates & Forecast, by Region, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.2.1 North America
β’ Market Estimates & Forecast, by Country, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.2.1.1 U.S.
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.2.1.2 Canada
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.2.2 South America
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3 Europe
β’ Market Estimates & Forecast, by Region, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1 Western Europe
β’ Market Estimates & Forecast, by Country, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.1 Germany
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.2 France
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.3 U.K.
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.4 Italy
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.5 Spain
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.1.6 Rest of Western Europe
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.3.2 Eastern Europe
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4 Asia Pacific
β’ Market Estimates & Forecast, by Country, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.1 Japan
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.2 China
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.3 India
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.4 Australia
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.5 Republic of Korea
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.4.6 Rest of Asia Pacific
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5 The Middle East & Africa
β’ Market Estimates & Forecast, by Region, 2020β2027
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.1 United Arab Emirates
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.2 Saudi Arabia
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.3 Oman
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.4 Kuwait
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.5 Qatar
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
10.5.6 Rest of the Middle East & Africa
β’ Market Estimates & Forecast, by Type, 2020β2027
β’ Market Estimates & Forecast, by Treatment, 2020β2027
β’ Market Estimates & Forecast, by Diagnosis, 2020β2027
β’ Market Estimates & Forecast, by End-User, 2020β2027
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Bayer AG
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Ferring B.V.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Johnson & Johnson Consumer Inc.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Novartis
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Merck KGaA
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Pfizer Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Specialty European Pharma
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Urit Medical Electronic Group Co., Ltd
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Roche Diagnostics
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Danaher Corporation
12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.12 Sysmex Corporation
12.12.1 Overview
12.12.2 Product Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.12 Acon Laboratories, Inc.
12.12.1 Overview
12.12.2 Product Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.13 Elektronika Kft.
12.13.1 Overview
12.13.2 Product Overview
12.13.3 Financials
12.13.4 Key Developments
12.13.5 SWOT Analysis
12.14 Mindray Medical International Limited
12.14.1 Overview
12.14.2 Product Overview
12.14.3 Financials
12.14.4 Key Developments
12.14.5 SWOT Analysis
12.15 Arkray, Inc.
12.15.1 Overview
12.15.2 Product Overview
12.15.3 Financials
12.15.4 Key Developments
12.15.5 SWOT Analysis
13 Appendix
LIST OF TABLES
Table 1 Adenomyosis Industry Synopsis, 2020β2027
Table 2 Global Adenomyosis Market Estimates and Forecast, 2020β2027, (USD Million)
Table 3 Global Adenomyosis Market, by Region, 2020β2027, (USD Million)
Table 4 Global Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 5 Global Adenomyosis Market, by Diagnosis, 2020β2027, (USD Million)
Table 6 Global Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 7 North America Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 8 North America Adenomyosis Market, by Diagnosis, 2020β2027, (USD Million)
Table 9 North America Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 10 U.S. Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 11 U.S. Adenomyosis Market, by Diagnosis, 2020β2027, (USD Million)
Table 12 U.S. Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 13 Canada Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 14 Canada Adenomyosis Market, by Diagnosis, 2020β2027, (USD Million)
Table 15 Canada Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 16 South America Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 17 South America Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 18 Europe Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 19 Europe Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 20 Western Europe Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 21 Western Europe Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 22 Eastern Europe Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 23 Eastern Europe Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 24 Asia Pacific Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 25 Asia Pacific Adenomyosis Market, by End-User, 2020β2027, (USD Million)
Table 26 Middle East & Africa Adenomyosis Market, by Treatment, 2020β2027, (USD Million)
Table 27 Middle East & Africa Adenomyosis Market, by diagnosis, 2020β2027, (USD Million)
Table 28 Middle East & Africa Adenomyosis Market, by End-User, 2020β2027, (USD Million)
β
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Adenomyosis Market
Figure 3 Segmentation Market Dynamics for Adenomyosis Market
Figure 4 Global Adenomyosis Market Share, by Treatment, 2020
Figure 5 Global Adenomyosis Market Share, by Diagnosis, 2020
Figure 6 Global Adenomyosis Market Share, by End-User, 2020
Figure 7 Global Adenomyosis Market Share, by Region, 2020
Figure 8 North America Adenomyosis Market Share, by Country, 2020
Figure 9 Europe Adenomyosis Market Share, by Country, 2020
Figure 10 Asia Pacific Adenomyosis Market Share, by Country, 2020
Figure 11 Middle East & Africa Adenomyosis Market Share, by Country, 2020
Figure 12 Global Adenomyosis Market: Company Share Analysis, 2020 (%)
Figure 13 Merck KGaA: Key Financials
Figure 14 Merck KGaA: Segmental Revenue
Figure 16 Merck KGaA: Geographical Revenue
Figure 17 Pfizer, Inc.. Key Financials
Figure 18 Pfizer, Inc.: Segmental Revenue
Figure 19 Pfizer, Inc.: Geographical Revenue
Figure 20 Danaher Corporation: Key Financials
Figure 21 Danaher Corporation: Segmental Revenue
Figure 22 Danaher Corporation: Geographical Revenue
Figure 23 Bayer AG: Key Financials
Figure 24 Bayer AG: Segmental Revenue
Figure 25 Bayer AG: Geographical Revenue
Figure 26 Novartis AG: Key Financials
Figure 27 Novartis AG: Segmental Revenue
Figure 28 Novartis AG. Geographical Revenue
Figure 29 Roche Diagnostic. Key Financials
Figure 30 Roche Diagnostic. Segmental Revenue
Figure 31 Roche Diagnostic. Geographical Revenue
The adenomyosis market is expected to register a CAGR of 4.5% during the forecast period, 2018–2023. The adenomyosis market is majorly driven by the high prevalence of urinary tract infections, rise in fibroid removal surgeries, increasing infection rates, rising population of women aged 40 and above, rising demand for technical advancements, increasing number of regulatory approvals, and growing penetration by market players. Additionally, factors such as the increasing funding for research and development initiatives in advanced medical treatment options are likely to drive the market. However, factors such as lack of awareness regarding causes and symptoms of adenomyosis are likely to hamper the growth of the market.
Market Segmentation
The adenomyosis market is segmented on the basis of type, treatment, diagnosis, and end-user. Considering type, the market is segmented into focal, adenomyoma, and diffuse. With reference to treatment, the market is segmented into anti-inflammatory drugs, hormone medications, and hysterectomy. By anti-inflammatory drugs, the market is sub-segmented into ibuprofen and naproxen. By hormone medications, the market is segmented into combined estrogen-progestin pills, vaginal rings, hormone-containing patches, and aromatase inhibitors. Based on diagnosis, the market is segmented into ultrasound, MRI, historiography, hysteroscopy, cystoscopy, and laparoscopy. By end-user, the market is segmented into hospitals and clinics, research institutes and ambulatory surgical centers, and others. Based on region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
North America is expected to hold the largest share of the adenomyosis market during the forecast period 2018–2023. The increasing prevalence of urinary tract infection is likely to enhance the growth of adenomyosis. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options along with the rising demand for technologically advanced treatments are likely to enhance the growth of the adenomyosis market in North America. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases, urinary infections are the most common bladder infections, and at least 40 to 60%of women develop a UTI during their lifetime.
Adenomyosis is a disease that occurs in women during their childbearing years. This disease is said to affect the mid-aged women and women who have had children. Women aged 40 and above are more prone to contract adenomyosis. According to the American U.S. Bureau, in 2016, around 10.57 million women were aged 40 and above. Additionally, according to the Government of Canada, in 2014 Canadas’ population comprised of 17.9 million females. This huge population of women aged 40 and above is expected to have a direct effect on the adenomyosis market as adenomyosis is known to affect mid-age women.
Europe is the second largest market and is expected to hold a healthy share in the adenomyosis market during the forecast period 2018–2023. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with the growing need for better healthcare infrastructure. Furthermore, increasing older women population along with the increasing prevalence of urinary infections is driving the growth of the adenomyosis market in Europe.
Asia Pacific is expected to be the fastest growing market. Factors such as the increasing prevalence of inflammatory disorders and injuries are the major drivers for the market growth. China is expected to be the fastest growing country due to increasing population and raising awareness about the health and availability of new treatment methods. Moreover, rising healthcare expenditure and improvement in the standard of living are driving the growth of the adenomyosis market in the Asia Pacific region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.
Research Methodology:
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Market Segmentation & Key players
Adenomyosis Market, by Type
Adenomyosis Market, by Treatment
Adenomyosis Market, by Diagnosis
Adenomyosis Market, by End-user
Adenomyosis Market, by Region
North America
South America
Europe
Asia Pacific
Middle East and Africa
Market Players
Intended Audience
Frequently Asked Questions (FAQ) :
Major treatments for adenomyosis include hormone medications and anti-inflammatory drugs.
Global adenomyosis market is expected to exhibit a strong 4.5% CAGR over the forecast period from 2020 to 2027.
The rising prevalence of urinary tract infections is the major driver for the adenomyosis market.
North America holds the largest share in the adenomyosis market.
Leading players in the adenomyosis market include Bayer, Novartis, and Pfizer, among others.